225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL
Two Late-Stage Platforms Targeting Inflammation- Driven Disease Corporate Presentation October 2026
Appoints Rare-Disease Executive and Biopharma Business Development Leader to Board
Other Events
Warrant Inducement Offer Agreement with Holders of April 2024 Warrants
Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
Stockholders Approve Amended 2021 Stock Incentive Plan with Share Increase
Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial
Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer’s Disease
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Schedule 13G - Ownership Report
Correspondence